MDXG — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-10-28

• During the third quarter of 2026, our performance reflected the execution of our strategic priorities against evolving market dynamics for our Surgical and Wound franchises, which experienced broadly lower procedure volume and reimbursement reform, respectively. The results also demonstrated our abi…

• •Net sales were $62 million, a decrease of 45% compared to the prior year period.

• ◦Our Surgical franchise, which accounted for 64% of our net sales, delivered 9% growth in the quarter. Surgical growth was driven by continued adoption of AMNIOFIX®, AMNIOEFFECT®, and our particulate portfolio, as well as contributions from G4Derm® Plus.

• ◦Our Wound franchise, which accounted for 36% of our net sales, meanwhile saw a 71% decline compared to the prior year period, due principally to the market disruptions driven by Medicare reimbursement changes implemented in 2026.

• •Gross margin was 80% during the quarter, representing an improvement of 11 percentage points compared to gross margin of 69% during the second quarter of 2026. The sequential improvement was primarily driven by improved production throughput, operational efficiencies, and the favorable impact of co…

Text removed vs the prior filing · source: 10-Q · 2026-07-29

• During the second quarter of 2026, we continued to execute our strategic priorities, including expanding our Surgical portfolio, launching new products, advancing recent cost reduction initiatives, and returning capital to shareholders through our Share Repurchase Plan. These efforts contributed to …

• •Net sales were $64 million, a decrease of 35% compared to the prior year period, driven by a 61% decline in Wound sales, partially offset by 15% growth in Surgical sales. Surgical growth was driven by continued adoption of AMNIOFIX®, AMNIOEFFECT®, and our particulate portfolio, as well as contribut…

• •We reported a GAAP net loss of $15 million or $0.10 per diluted share, and ended the quarter with $136 million of cash and cash equivalents.

• •During the quarter, we completed a reduction-in-force and implemented additional cost reduction initiatives designed to align our cost structure with current business needs and support operating efficiency.

• •Separately, we repurchased approximately $13 million of common stock under our Share Repurchase Plan, reflecting our continued commitment to disciplined capital allocation and delivering long-term shareholder value.

Text added vs the prior filing · source: 10-Q · 2026-10-28

• •the pending acquisition of Sanara MedTech Inc., including the expected timing of completion, the receipt of required regulatory and shareholder approvals, the anticipated financing of the transaction, and the anticipated benefits, costs and impact of the transaction on our business, results of oper…

Text added vs the prior filing · source: 10-Q · 2026-10-28

• •the pending acquisition of Sanara MedTech Inc., including the expected timing of completion, the receipt of required regulatory and shareholder approvals, the anticipated financing of the transaction, and the anticipated benefits, costs and impact of the transaction on our business, results of oper…

Text added vs the prior filing · source: 10-Q · 2026-10-28

• •the pending acquisition of Sanara MedTech Inc., including the expected timing of completion, the receipt of required regulatory and shareholder approvals, the anticipated financing of the transaction, and the anticipated benefits, costs and impact of the transaction on our business, results of oper…

Text added vs the prior filing · source: 10-Q · 2026-10-28

• An investment in our Common Stock involves a substantial risk of loss. You should carefully consider the risks described below, together with the other information contained in this Quarterly Report on Form 10-Q and the risk factors previously disclosed in Part I, Item 1A, “Risk Factors,” of our Ann…

• The completion of our pending acquisition of Sanara is subject to a number of conditions, including the expiration or termination of the applicable waiting period under the HSR Act, and other closing conditions set forth in the Merger Agreement.

• On October 15, 2026, we and Sanara each received a request for additional information and documentary materials (a “Second Request”) from the FTC in connection with the FTC’s review of the Acquisition. The effect of the Second Request is to extend the waiting period under the HSR Act until 30 days a…

• The Second Request may delay completion of the Acquisition and require us to devote significant time and resources to the regulatory review process. There can be no assurance as to the timing or outcome of the FTC’s review. The FTC could seek to prevent the Acquisition or impose conditions, limitati…

• If the Acquisition is delayed or not completed, we may incur significant expenses without realizing the anticipated benefits of the Acquisition. Failure to complete the Acquisition could also adversely affect our relationships with employees, customers and other business partners and could adversely…

Text removed vs the prior filing · source: 10-Q · 2026-07-29

• Item 2Unregistered Sales of Equity Securities and Use of Proceeds

• Explanatory Note and Important Cautionary Statement Regarding Forward-Looking Statements

• As used herein, the terms “MIMEDX,” the “Company,” “we,” “our” and “us” refer to MiMedx Group, Inc., a Florida corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only MiMedx Group, Inc.

• Certain statements made in this Quarterly Report on Form 10-Q (this “Quarterly Report”) are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and section 21E of the Securities Exchange Act of 1934, as amended. All stateme…

• •our strategic focus and current business priorities, including broadening of our product portfolio, and our ability to implement these priorities;

Text added vs the prior filing · source: 10-Q · 2026-10-28

• •the pending acquisition of Sanara MedTech Inc., including the expected timing of completion, the receipt of required regulatory and shareholder approvals, the anticipated financing of the transaction, and the anticipated benefits, costs and impact of the transaction on our business, results of oper…